Catherine R Lesko1, Michael J Mugavero2, Nicola M Shen1, Anthony T Fojo3, Richard D Moore3, Jeanne C Keruly3, Edward R Cachay4, Sonia Napravnik5,6, Kenneth H Mayer7,8,9, Katerina A Christopoulos10, Jeffrey M Jacobson11, Peter F Rebeiro12, Geetanjali Chander3. 1. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland. 2. Division of Infectious Diseases, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama. 3. School of Medicine, Johns Hopkins University, Baltimore, Maryland. 4. Department of Medicine, Division of Infectious Diseases and Global Public Health, University of California San Diego, San Diego, California. 5. Division of Infectious Diseases, Department of Medicine. 6. Department of Epidemiology, University of North Carolina, Chapel Hill, North Carolina. 7. The Fenway Institute, Fenway Health. 8. Department of Medicine, Beth Israel Deaconess Medical Center/Harvard Medical School. 9. Department of Global Health and Population, Harvard School of Public Health, Boston, Massachusetts. 10. Division of Infectious Diseases, HIV, and Global Medicine, Department of Medicine, University of California, San Francisco, San Francisco, California. 11. School of Medicine, Case Western Reserve University, Cleveland, Ohio. 12. Department of Medicine & Department of Biostatistics, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.
Abstract
OBJECTIVE: To describe retention in HIV care based on various definitions of retention in the modern treatment era. DESIGN: A cohort study of people enrolled in care at seven mostly urban HIV clinics across the United States, 2010-2018. METHODS: We estimated retention based on missed visits, kept visits, kept encounters (clinical visits, CD4 counts, and viral loads), and HIV labs. We contrasted risk factors for retention by different definitions and estimated odds ratios for of viral suppression and hazard ratios for mortality in 2 years immediately following the year in which retention was defined (the study year). RESULTS: Across 108 171 person-years (N = 21 481 people), in 71% of years people kept ≥75% of scheduled visits; in 78%, people kept ≥2 visits >90 days apart; in 74%, people had ≥2 HIV labs >90 days apart; and in 47%, people had no gaps >6 months in clinic visits. Missing >25% of scheduled visits despite attending ≥2 visits >90 days apart was associated with nonwhite non-Hispanic race/ethnicity, history of injection drug use, and prior AIDS diagnosis. In contrast, attending ≥75% of scheduled visits while not attending ≥2 visits >90 days apart was associated with male sex, white race, no injection drug use history, and no prior AIDS diagnosis. Subsequent viral nonsuppression was more strongly associated with missed- than kept-visit measures of retention; 2-year mortality was only associated with failure to be retained by missed-visit measures. DISCUSSION: Missed and kept-visit definitions of retention capture different constructs. Missed-visit measures are more strongly associated with poor HIV outcomes.
OBJECTIVE: To describe retention in HIV care based on various definitions of retention in the modern treatment era. DESIGN: A cohort study of people enrolled in care at seven mostly urban HIV clinics across the United States, 2010-2018. METHODS: We estimated retention based on missed visits, kept visits, kept encounters (clinical visits, CD4 counts, and viral loads), and HIV labs. We contrasted risk factors for retention by different definitions and estimated odds ratios for of viral suppression and hazard ratios for mortality in 2 years immediately following the year in which retention was defined (the study year). RESULTS: Across 108 171 person-years (N = 21 481 people), in 71% of years people kept ≥75% of scheduled visits; in 78%, people kept ≥2 visits >90 days apart; in 74%, people had ≥2 HIV labs >90 days apart; and in 47%, people had no gaps >6 months in clinic visits. Missing >25% of scheduled visits despite attending ≥2 visits >90 days apart was associated with nonwhite non-Hispanic race/ethnicity, history of injection drug use, and prior AIDS diagnosis. In contrast, attending ≥75% of scheduled visits while not attending ≥2 visits >90 days apart was associated with male sex, white race, no injection drug use history, and no prior AIDS diagnosis. Subsequent viral nonsuppression was more strongly associated with missed- than kept-visit measures of retention; 2-year mortality was only associated with failure to be retained by missed-visit measures. DISCUSSION: Missed and kept-visit definitions of retention capture different constructs. Missed-visit measures are more strongly associated with poor HIV outcomes.
Authors: Julia C Dombrowski; Susan E Buskin; Amy Bennett; Hanne Thiede; Matthew R Golden Journal: J Acquir Immune Defic Syndr Date: 2014-11-01 Impact factor: 3.731
Authors: Jacek Skarbinski; Eli Rosenberg; Gabriela Paz-Bailey; H Irene Hall; Charles E Rose; Abigail H Viall; Jennifer L Fagan; Amy Lansky; Jonathan H Mermin Journal: JAMA Intern Med Date: 2015-04 Impact factor: 21.873
Authors: Michael J Mugavero; Hui-Yi Lin; Jeroan J Allison; Thomas P Giordano; James H Willig; James L Raper; Nelda P Wray; Stephen R Cole; Joseph E Schumacher; Susan Davies; Michael S Saag Journal: J Acquir Immune Defic Syndr Date: 2009-01-01 Impact factor: 3.731
Authors: Michael S Saag; Rajesh T Gandhi; Jennifer F Hoy; Raphael J Landovitz; Melanie A Thompson; Paul E Sax; Davey M Smith; Constance A Benson; Susan P Buchbinder; Carlos Del Rio; Joseph J Eron; Gerd Fätkenheuer; Huldrych F Günthard; Jean-Michel Molina; Donna M Jacobsen; Paul A Volberding Journal: JAMA Date: 2020-10-27 Impact factor: 56.272
Authors: Melanie A Thompson; Michael A Horberg; Allison L Agwu; Jonathan A Colasanti; Mamta K Jain; William R Short; Tulika Singh; Judith A Aberg Journal: Clin Infect Dis Date: 2021-12-06 Impact factor: 9.079
Authors: Peter F Rebeiro; Michael A Horberg; Stephen J Gange; Kelly A Gebo; Baligh R Yehia; John T Brooks; Kate Buchacz; Michael J Silverberg; John Gill; Richard D Moore; Keri N Althoff Journal: PLoS One Date: 2014-11-06 Impact factor: 3.240
Authors: Jessie K Edwards; Stephen R Cole; Daniel Westreich; Richard Moore; Christopher Mathews; Elvin Geng; Joseph J Eron; Michael J Mugavero Journal: PLoS One Date: 2014-07-10 Impact factor: 3.240
Authors: Catherine R Lesko; Jessie K Edwards; David B Hanna; Angel M Mayor; Michael J Silverberg; Michael Horberg; Peter F Rebeiro; Richard D Moore; Ashleigh J Rich; Kathleen A McGinnis; Kate Buchacz; Heidi M Crane; Charles S Rabkin; Keri N Althoff; Tonia C Poteat Journal: AIDS Date: 2022-07-21 Impact factor: 4.632